Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Relevance of Antibody Validation for Flow Cytometry

T. Kalina, K. Lundsten, P. Engel

. 2020 ; 97 (2) : 126-136. [pub] 20191002

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026759
E-zdroje Online Plný text

NLK Free Medical Journals od 2003 do Před 1 rokem
Medline Complete (EBSCOhost) od 2012-06-01 do Před 1 rokem
Wiley Free Content od 2003 do Před 1 rokem

Antibody reagents are the key components of multiparametric flow cytometry analysis. Their quality performance is an absolute requirement for reproducible flow cytometry experiments. While there is an enormous body of antibody reagents available, there is still a lack of consensus about which criteria should be evaluated to select antibody reagents with the proper performance, how to validate antibody reagents for flow cytometry, and how to interpret the validation results. The achievements of cytometry moved the field to a higher number of measured parameters, large data sets, and computational data analysis approaches. These advancements pose an increased demand for antibody reagent performance quality. This review summarizes the codevelopment of cytometry, antibody development, and validation strategies. It discusses the diverse issues of the specificity, cross-reactivity, epitope, titration, and reproducibility features of antibody reagents, and this review discusses the validation principles and methods that are currently available and those that are emerging. We argue that significant efforts should be invested by antibody users, developers, manufacturers, and publishers to increase the quality and reproducibility of published studies. More validation data should be presented by all stakeholders; however, the data should be presented in sufficient experimental detail to foster reproducibility, and community effort shall lead to the public availability of large data sets that can serve as a benchmark for antibody performance. © 2019 International Society for Advancement of Cytometry.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026759
003      
CZ-PrNML
005      
20211026132632.0
007      
ta
008      
211013s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cyto.a.23895 $2 doi
035    __
$a (PubMed)31577065
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kalina, Tomas $u CLIP-Childhood Leukemia Investigation Prague, Department of Pediatric Hematology and Oncology, 2nd Medical School, Charles University and University Hospital Motol, Prague, Czech Republic
245    10
$a Relevance of Antibody Validation for Flow Cytometry / $c T. Kalina, K. Lundsten, P. Engel
520    9_
$a Antibody reagents are the key components of multiparametric flow cytometry analysis. Their quality performance is an absolute requirement for reproducible flow cytometry experiments. While there is an enormous body of antibody reagents available, there is still a lack of consensus about which criteria should be evaluated to select antibody reagents with the proper performance, how to validate antibody reagents for flow cytometry, and how to interpret the validation results. The achievements of cytometry moved the field to a higher number of measured parameters, large data sets, and computational data analysis approaches. These advancements pose an increased demand for antibody reagent performance quality. This review summarizes the codevelopment of cytometry, antibody development, and validation strategies. It discusses the diverse issues of the specificity, cross-reactivity, epitope, titration, and reproducibility features of antibody reagents, and this review discusses the validation principles and methods that are currently available and those that are emerging. We argue that significant efforts should be invested by antibody users, developers, manufacturers, and publishers to increase the quality and reproducibility of published studies. More validation data should be presented by all stakeholders; however, the data should be presented in sufficient experimental detail to foster reproducibility, and community effort shall lead to the public availability of large data sets that can serve as a benchmark for antibody performance. © 2019 International Society for Advancement of Cytometry.
650    12
$a protilátky $7 D000906
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a indikátory a reagencie $7 D007202
650    _2
$a reprodukovatelnost výsledků $7 D015203
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Lundsten, Kelly $u BioLegend, Inc, San Diego, CA, USA
700    1_
$a Engel, Pablo $u Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
773    0_
$w MED00013935 $t Cytometry. Part A : the journal of the International Society for Analytical Cytology $x 1552-4930 $g Roč. 97, č. 2 (2020), s. 126-136
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31577065 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132638 $b ABA008
999    __
$a ok $b bmc $g 1715491 $s 1147266
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 97 $c 2 $d 126-136 $e 20191002 $i 1552-4930 $m Cytometry. Part A $n Cytometry A $x MED00013935
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...